HiDiamond Biotechnology closes nearly RMB 100 million Pre-A series funding round

HiDiamond Biotechnology Co.,Ltd ("HiDiamond") recently announced the completion of a nearly RMB 100 million Pre-A round of financing. This round was led by Northern Light Venture Capital, with follow-on investments from Dongwei Fund, DCG Holdings, CDH Investments, and Future Innovation Fund. The angel round investor, Xingyao Taihao Fund, continued to add investment. The successful completion of this financing round highlights the strong recognition of HiDiamond's innovative R&D model and early-stage achievements by international capital, industry funds, and multiple local governments, providing robust momentum for the enrichment and advancement of the company's innovative pipeline.

HiDiamond Biotechnology is a biopharmaceutical company dedicated to developing globally leading therapeutic products and innovative drug targets. Operating under a "Hub and Spoke" model, the company leverages the extensive industry expertise of its founders and team, along with specialist and industrial resources, to rapidly advance a diverse portfolio of high-value pipelines. By capitalizing on the integrated cost and efficiency advantages of China's biopharmaceutical sector, HiDiamond drives efficient development and actively competes in the global market.

The company's lead product, the HiD21 series, is a novel molecular entity designed against highly specific targets and demonstrates exceptional development efficiency. It is currently in Phase I clinical trials, targeting indications with significant unmet medical needs including hematologic malignancies, advanced solid tumors, and autoimmune diseases. HiDiamond has also initiated multiple follow-up R&D programs, building a sustainable pipeline that supports long-term growth.

The funds from this financing round will primarily be used to enrich and advance preclinical and clinical proof-of-concept (POC) studies of existing pipelines. Additionally, the company will fully deploy AI platforms and bio-organoid platforms in drug R&D and evaluation, focusing on building core capabilities in target and molecular druggability assessment, molecular and experimental design, and multi-dimensional outcome evaluation. This will effectively enhance project initiation and decision-making efficiency as well as R&D success rates.